{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:12:25Z","timestamp":1777864345433,"version":"3.51.4"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections, while effective therapeutic options remain limited. This study investigated the antiviral efficacy, pharmacokinetics, and safety of aerosolized human interferon-\u03b11b (IFN-\u03b11b) as a potential treatment for RSV infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The antiviral activity of IFN-\u03b11b against RSV was evaluated\n                      <jats:italic>in vitro<\/jats:italic>\n                      and in an RSV-infected mouse model. Pharmacokinetics, tissue distribution, and repeat-dose inhalation toxicity were assessed in cynomolgus monkeys.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      IFN-\u03b11b inhibited RSV\n                      <jats:italic>in vitro<\/jats:italic>\n                      (EC\u2085\u2080 of 4.64\u202fng\/mL). In mice, aerosolized IFN-\u03b11b reduced lung viral titers in a dose-dependent manner. Notably, the reduction in viral load across all IFN-\u03b11b dose groups was greater than that observed in the ribavirin-treated group under the conditions tested (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). In monkeys, inhalation resulted in high respiratory drug exposure with an absolute systemic bioavailability of 3.33%. Repeated dosing (18\u202f\u03bcg\/kg\/day) was well tolerated, with only minimal to mild (Grade 1 to 2) focal lung inflammation that was fully reversible.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Aerosolized IFN-\u03b11b demonstrates antiviral activity and favorable lung-targeted pharmacokinetics in preclinical models, supporting further investigation in clinical settings. It was associated with greater reduction in lung viral titers compared with ribavirin in this model while maintaining a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1767720","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:40:18Z","timestamp":1777527618000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Aerosol inhalation of human IFN-\u03b11b exhibits anti-RSV activity in mice and favorable pharmacokinetics\/safety in cynomolgus monkeys"],"prefix":"10.3389","volume":"17","author":[{"given":"Mingming","family":"Yang","sequence":"first","affiliation":[{"name":"Shenzhen Kexing Pharmaceutical Co., Ltd","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Microbiology, School of Basic Medicine, Guangxi Medical University","place":["Nanning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanran","family":"Wang","sequence":"additional","affiliation":[{"name":"Capital Center for Children\u2019s Health, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangtao","family":"Bai","sequence":"additional","affiliation":[{"name":"Shenzhen Kexing Pharmaceutical Co., Ltd","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowen","family":"Liang","sequence":"additional","affiliation":[{"name":"Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahua","family":"Kuang","sequence":"additional","affiliation":[{"name":"Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjie","family":"Ma","sequence":"additional","affiliation":[{"name":"Shenzhen Kexing Pharmaceutical Co., Ltd","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/13543784.2020.1735349","article-title":"Emerging small and large molecule therapeutics for respiratory syncytial virus","volume":"29","author":"Bergeron","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1128\/AAC.00737-17","article-title":"Preclinical characterization of PC786, an inhaled small-molecule respiratory syncytial virus L protein polymerase inhibitor","volume":"61","author":"Coates","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1021\/acs.jmedchem.8b01361","article-title":"State of the art in respiratory syncytial virus drug discovery and development","volume":"62","author":"Cockerill","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"9350","DOI":"10.1128\/JVI.00818-14","article-title":"Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection","volume":"88","author":"Cormier","year":"2014","journal-title":"J. Virol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.hlife.2023.09.003","article-title":"A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein","volume":"1","author":"Dai","year":"2023","journal-title":"hLife"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1164\/rccm.201002-0221OC","article-title":"Viral load drives disease in humans experimentally infected with respiratory syncytial virus","volume":"182","author":"DeVincenzo","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2016.08.006","article-title":"New antiviral approaches for respiratory syncytial virus and other mononegaviruses: inhibiting the RNA polymerase","volume":"134","author":"Fearns","year":"2016","journal-title":"Antivir. Res."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.15585\/mmwr.mm7241e1","article-title":"Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the advisory committee on immunization practices - United States, 2023","volume":"72","author":"Fleming-Dutra","year":"2023","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.3390\/v15122417","article-title":"Respiratory syncytial virus reinfections in children in Western Australia","volume":"15","author":"Foley","year":"2023","journal-title":"Viruses"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1093\/infdis\/jiy655","article-title":"Viral load dynamics and clinical disease severity in infants with respiratory syncytial virus infection","volume":"219","author":"Garcia-Mauri\u00f1o","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/pathogens12020154","article-title":"Prevention and treatment strategies for respiratory syncytial virus (RSV)","volume":"12","author":"Gatt","year":"2023","journal-title":"Pathogens"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"6128","DOI":"10.1128\/JVI.00333-14","article-title":"Alpha\/beta interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection","volume":"88","author":"Goritzka","year":"2014","journal-title":"J. Virol."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1128\/CMR.00010-16","article-title":"Respiratory syncytial virus: infection, detection, and new options for prevention and treatment","volume":"30","author":"Griffiths","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"10190","DOI":"10.1128\/JVI.79.16.10190-10199.2005","article-title":"Activity and regulation of alpha interferon in respiratory syncytial virus and human metapneumovirus experimental infections","volume":"79","author":"Guerrero-Plata","year":"2005","journal-title":"J. Virol."},{"key":"ref16","first-page":"17","article-title":"RSV respiratory infection in children under 5 y.o.--dynamics of the immune response Th1\/Th2 and IgE","volume":"67","author":"Gut","year":"2013","journal-title":"Przegl. Epidemiol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3892\/etm.2020.9350","article-title":"Efficacy and safety of interferon on neonates with respiratory syncytial virus pneumonia","volume":"20","author":"He","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"11034","DOI":"10.1038\/s41598-018-29456-w","article-title":"Type I interferon potentiates IgA immunity to respiratory syncytial virus infection during infancy","volume":"8","author":"Hijano","year":"2018","journal-title":"Sci. Rep."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3389\/fimmu.2019.00566","article-title":"Role of type I interferon (IFN) in the respiratory syncytial virus (RSV) immune response and disease severity","volume":"10","author":"Hijano","year":"2019","journal-title":"Front. Immunol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"S282","DOI":"10.1093\/infdis\/jiac216","article-title":"Expected impact of universal immunization with Nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model","volume":"226","author":"Kieffer","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.jinf.2015.04.025","article-title":"New options in the treatment of respiratory syncytial virus disease","volume":"71","author":"Mejias","year":"2015","journal-title":"J. Infect."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S2352-4642(22)00092-X","article-title":"Prevalence of respiratory viruses in community-acquired pneumonia in children: a systematic review and meta-analysis","volume":"6","author":"Pratt","year":"2022","journal-title":"Lancet Child Adolescent Health"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e1007984","DOI":"10.1371\/journal.ppat.1007984","article-title":"Respiratory syncytial virus nonstructural proteins 1 and 2: exceptional disrupters of innate immune responses","volume":"15","author":"Sedeyn","year":"2019","journal-title":"PLoS Pathog."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e2576","DOI":"10.1002\/rmv.2576","article-title":"Systematic review of the efficacy and safety of RSV-specific monoclonal antibodies and antivirals in development","volume":"34","author":"Sevendal","year":"2024","journal-title":"Rev. Med. Virol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.7150\/ijbs.64762","article-title":"Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies","volume":"17","author":"Shang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s41061-017-0129-4","article-title":"Recent advances in developing antiviral therapies for respiratory syncytial virus","volume":"375","author":"Shook","year":"2017","journal-title":"Topics Curr. Chem."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1093\/infdis\/jiu828","article-title":"Challenges and opportunities in developing respiratory syncytial virus therapeutics","volume":"211","author":"Sim\u00f5es","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1097\/INF.0b013e3181ff2fac","article-title":"The relationship between respiratory viral loads and diagnosis in children presenting to a pediatric hospital emergency department","volume":"30","author":"Utokaparch","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1021\/jm5017279","article-title":"Discovery of 4\u2032-chloromethyl-2\u2032-deoxy-3\u2032,5\u2032-di-O-isobutyryl-2\u2032-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection","volume":"58","author":"Wang","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.apsb.2025.02.015","article-title":"Advances in development of antiviral strategies against respiratory syncytial virus","volume":"15","author":"Yang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jped.2020.12.005","article-title":"The effect of recombinant human interferon \u03b11b treatment of infants hospitalized with lower respiratory tract infection on subsequent wheezing","volume":"97","author":"Yang","year":"2021","journal-title":"J. Pediatr."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1767720\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:40:21Z","timestamp":1777527621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1767720\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":35,"alternative-id":["10.3389\/fmicb.2026.1767720"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1767720","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"1767720"}}